Clearside Biomedical (NSDQ:CLSD) shares soared more than 50% in pre-market activity today after the company reported that its suprachoroidal eye drug succeeded in a pivotal Phase III trial of patients with macular edema associated with non-infectious uveitis.
The company’s drug, CLS-TA, is a proprietary suspension of a corticosteroid, triamcinolone acetonide, designed to be administered to the back of the eye via the suprachoroidal space.
Get the full story at our sister site, Drug Delivery Business News.
The post Clearside Biomedical shares soar after eye drug succeeds in Ph3 trial appeared first on MassDevice.